Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

European approval recommended for Lysodren

Jan. 27, 2004

CPMP recommends extension of Paxene indications

Jan. 27, 2004

CR-4: a novel tyrosine kinase inhibitor active against ALL and AML cell lines

Jan. 27, 2004

Onyvax and Mayo Clinic to develop cancer vaccines for ovarian cancer

Jan. 26, 2004

Zevalin radioimmunotherapy receives European approval

Jan. 26, 2004

CytoGenix and Baylor to test aerosol gene silencing agent on mouse lung cancer

Jan. 23, 2004

OSI commences rolling NDA submission for Tarceva for NSCLC

Jan. 23, 2004

PI-88 enters phase II melanoma trial

Jan. 23, 2004

Tubercin shows activity in mouse metastatic melanoma

Jan. 23, 2004

Mercian and Eisai present novel VEGF production inhibitors for cancer therapy

Jan. 23, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...